Skip to main content
Premium Trial:

Request an Annual Quote

Legislation Approved To Raise Cap On H1B Visa Limits, Awaits Clinton s Signature


WASHINGTON--President Clinton is expected to sign legislation this month to raise the number of temporary work visas available to highly skilled foreign workers employed by US companies.

The measure, approved by Congress in late September, increases to 115,000 the number of H1B visas that may be issued in a year through 2000. The bill reduces the cap to 107,500 in 2001 and returns it to the current limit of 65,000 in 2002.

But immigration attorney Lawrence Bastone of Cambridge, Mass., whose clientele includes genomics and life sciences companies, argued that increasing the number of visas available is not enough.

He said the government should "unencumber" the process of securing an H1B visa.

The new legislation requires employers to show that a qualified US candidate was not available for a position being filled by an H1B visa applicant and prohibits employers who use H1B visas from laying off US workers in similar job categories for six months.

According to the business community, thousands of high-tech and scientific jobs have gone unfilled since this year's limit of 65,000 was reached in May. In addition to private-sector employers, universities will also benefit from the new law.

Filed under

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.